All In Biotech

Drug Trial Radar · NCT06730022

Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Merakris TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.

Conditions

  • Cutaneous Ulcer
  • Diabetic Ulcer
  • Surgical Wound Dehiscence
  • Burns - Multiple
  • Pressure Ulcers
  • Mixed Ulcer
  • Ischemic Ulcer

Interventions

  • MTX-001 (Dermacyte Liquid)Drug

    Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The WISH Clinic

    Arvada, Colorado · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.